Benzinga | Jan 11, 2021 07:02AM EST

CureVac Says Its COVID-19 Vaccine Candidate, CVnCoV Demonstrated Efficient Protection Of Non-Human Primates During SARS-CoV-2 Challenge Infection

CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection



. Data provided further evidence on immunogenicity and protective efficacy of CVnCoV

. Induction of robust antibody and T cell responses at comparable dose tested in clinical trials

. Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection



T?BINGEN, Germany/ BOSTON, USA -- January 11, 2021 -- CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 following vaccination with 8?g of CVnCoV. The data provided important evidence on the immunogenicity and protective efficacy of CVnCoV at low doses, supporting the ongoing international clinical Phase 2b/3 efficacy study applying a 12?g dose. The full manuscript of the preclinical data is available on the pre-print server bioRxiv.



"These data further strengthen the protective profile of our lead COVID-19 vaccine candidate, CVnCoV, and complement our recently published preclinical findings," said Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac. "Full protection of the lungs of vaccinated animals supports CVnCoV's potential in protecting humans from the devastating effects the virus has. We are very encouraged to see that CVnCoV exihibits its protective efficacy already at a low dose, which is even lower than the dose we advanced into late-stage human clinical testing."



Within the study, CVnCoV was tested in rhesus macaques at 8?g per dose following a two-dose vaccination schedule at day 0 and day 28. Robust humoral and cellular immune responses include high levels of spike protein and RBD specific binding, virus neutralizing antibodies and T cells. Upon challenge infection, vaccinated animals showed a strongly reduced viral load in the upper respiratory tract (nose and throat) and full protection of the lower respiratory tract (lungs), where the virus was not detectable.



About CVnCoV

CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020. The vaccine is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nano Particles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. The data supported CureVac's decision to advance a 12?g dose into its current pivotal Phase 2b/3 study, the HERALD study, which started in December 2020. Clinical trial material is provided by the company's substantial production capacities for mRNA vaccines at its headquarters in T?bingen, supported by the current expansion of manufacturing capacities in Europe, allowing broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.